Patent intelligence · US
US 6242482
Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congesti…
Patent details — US 6242482
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 5, 2001
- Expiration
- May 31, 2021
- Applicant
- United Therapeutics Corporation
- Claims
- 51
- CPC classes
- A61K, A61K31/192, A61K31/222, A61K31/5585
Quick answer
US 6242482 (Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure) is held by United Therapeutics Corporation. Status: expired. Granted Jun 5, 2001. Expires May 31, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- United Therapeutics Corporation
- Grant date
- Expiration
- Claims
- 51
- CPC classes
- A61K, A61K31/192, A61K31/222, A61K31/5585, A61K47/60, A61K9/0073
More from United Therapeutics Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 6242482?
US 6242482 (Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure) is held by United Therapeutics Corporation. Status: expired. Granted Jun 5, 2001. Expires May 31, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6242482?
United Therapeutics Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 6242482 expire?
Our index shows an expiration date of May 31, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.